Get started
Verona Pharma plc Sponsored ADRVerona Pharma plc Sponsored ADRVerona Pharma plc Sponsored ADR

Verona Pharma plc Sponsored ADR

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonalsOptionsETFs

VRNA chart


Full chart

VRNA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪9.19 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.02 USD
Net income (FY)
‪−173.49 M‬ USD
Revenue (FY)
‪42.30 M‬ USD
Shares float
‪78.31 M‬
Beta (1Y)
1.55

About Verona Pharma plc Sponsored ADR


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David S. Zaccardelli
Website
veronapharma.com
Headquarters
London
Founded
2005
ISIN
US9250501064
FIGI
BBG00GD4KBL1
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Check out other big names from the same industry as VRNA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VRNA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs with VRNA exposure


FCLC
Fidelity Canadian Large Cap Fund ETF Series ETF Trust Units
Weight
1.86%
Market value
‪156.61 M‬
USD
IBB
iShares Biotechnology ETF
Weight
0.56%
Market value
‪34.87 M‬
USD
FGEP
Fidelity Global Equity+ Fund Trust Units
Weight
0.60%
Market value
‪27.29 M‬
USD
SPDW
SPDR Portfolio Developed World ex-US ETF
Weight
0.03%
Market value
‪7.81 M‬
USD
BTEC
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.81%
Market value
‪5.18 M‬
USD
BTEE
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.81%
Market value
‪5.18 M‬
USD
SBIO
Invesco NASDAQ Biotech UCITS ETF
Weight
0.81%
Market value
‪3.12 M‬
USD
ARB
AltShares Merger Arbitrage ETF
Weight
3.33%
Market value
‪2.98 M‬
USD
ONEQ
Fidelity Nasdaq Composite Index ETF
Weight
0.03%
Market value
‪2.28 M‬
USD
FGEB
Fidelity Global Equity+ Balanced Fund Trust Units
Weight
0.34%
Market value
‪819.58 K‬
USD
ARB
Accelerate Arbitrage Fund ETF
Weight
2.92%
Market value
‪801.26 K‬
USD

Explore more ETFs